Davis Polk & Wardwell and Jia Yuan Law Offices have advised Chinese clinical trial and research firm Hangzhou Tigermed Consulting on its $1.38 billion Hong Kong IPO, with Freshfields Bruckhaus Deringer and Zhong Lun Law Firm representing the sponsors.

Tigermed, which is already listed in Shenzhen, is the largest clinical research trial provider in mainland China. According to Reuters, Tigermed will sell 107.06 million shares in this IPO, which could make the deal the largest healthcare transaction in Asia this year, topping WuXi Biologics’ $984 million share placement in May.

The Jia Yuan Law Offices team advising on the deal was led by partners Wang Yuan and Fu Yangyuan.

Meanwhile, partners Zhang Jinquan, Zhu Ying, Zhong Yang and Li Xiang led the Zhong Lun Law Firm team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Features

MIDDLE EAST: IPO Oasis

by Nimitt Dixit |

The Middle East’s regional IPO markets are flourishing despite a global slowdown and geopolitical instability owing to the region’s long-term structural and regulatory reforms, a maturing diversified market and strong investor confidence.

Deals

CC, Paul Hastings lead on CR Beverages’ HK IPO

by Charlie Wu 吴卓言 |

Clifford Chance and Jingtian & Gongcheng are advising China Resources Beverages, the beverage division of the state-owned China Resources Enterprise, on its upcoming Hong Kong IPO, which is expected to raise up to $1 billion. Paul Hastings and Zhong Lun Law Firm are acting for the joint sponsors.

Deals

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.